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ABSTRACT
Interferons (IFNs) are the key components of innate immunity and are crucial for host
defense against viral infections. Here, we report a novel role of interleukin-17A (IL-17A)
in inhibiting IFN-α2 expression, thus promoting chikungunya virus (CHIKV) infection.
CHIKV infected IL-17A deficient (Il17a-/-) mice expressed a higher level of IFN-α2 and
developed diminished viremia and milder footpad swelling in comparison to wild-type
(WT) control mice, this was also recapitulated in IL-17A receptor-deficient (Il17ra-/-)
mice. Interestingly, IL-17A selectively blocked IFN-α2 production during CHIKV, but
not West Nile virus (WNV) or Zika virus (ZIKV), infections. Recombinant IL-17A
treatment inhibited CHIKV-induced IFN-α2 expression and enhanced CHIKV replication
in both human and mouse cells. We further found that IL-17A inhibited IFN-α2
production by modulating the expression of Interferon Regulatory Factor-5 (IRF-5), IRF7, IFN-stimulated gene 49 (ISG-49), and Mx1 expression during CHIKV infection.
Neutralization of IL-17A in vitro leads to the increase of the expression of these antiviral
molecules and the decrease of CHIKV replication. Collectively, these results suggest a
novel function of IL-17A in inhibiting IFN-α2-mediated antiviral responses during
CHIKV infection, which may have broad implications in viral infections and other
inflammatory diseases.
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CHAPTER I - INTRODUCTION
1.1 Chikungunya virus
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus causing a
febrile illness mainly characterized by joint pain. It is a single-stranded, positive sensed
virus of the family Togaviridae. It belongs to the genus Alphavirus, which contains 30
species of arthropod-borne viruses sharing seven specific antigenic complexes (Calisher
and Karabatsos, 1988). Among those, CHIKV is closely related to arthritis causing Ross
River virus, Barmah Forest virus, O’nyong-nyong virus, Mayaro virus, and the Sindbis
group of viruses (Kiwanuka et al, 1999; Laine et al, 2004; Munoz and Navarro, 2012;
Phillips et al, 1990; Suhrbier and Linn, 2004). CHIKV was first reported in the midtwentieth century (Robinson, 1995). Since then, it has been transmitted to a large
geographical area and has been one of the major public health concerns in the tropical,
subtropical, and the temperate areas. There are three genotypes of CHIKV which are
named after their geographical distributions: Asian, West African, and East Central South
African. Chikungunya fever presents clinical, and laboratory features like dengue fever,
hence symptomatic diagnosis presents some clinical confusions, but the presence of
arthralgia in the febrile cases is the distinguishing factor for CHIKV fever.
1.1.1 Structure and Genome
CHIKV is an enveloped, spherical virus, approximately 60-70 nm in diameter
(Robinson, 1995; Christie, 1881; Carey, 1971). The positive-stranded RNA genome
consists of 5’cap-nsP1-nsP2-nsP3-nsP4-(junction region)-C-E3-E2-6K-E1-poly(A)-3’.
The 5’ non-translatable region (NTR) and 3’ NTR of the genome are composed of 76
nucleotides and 526 nucleotides, respectively. Alphavirus genomes are capped at 5’ end,
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polyadenylated at 3’ end, and consists of two open reading frames coding for four nonstructural proteins (nsP1 to nsP4), three structural proteins (capsid, E1, E2), and two small
cleavage products (E3 and 6K) (Simizu et al, 1984; Higashi et al, 1967). The CHIKV
genome is packaged by the C-protein to form a nucleocapsid which is further surrounded
by an envelope layer. The two transmembrane glycoproteins, E1 and E2, are arranged in
an icosahedral symmetry and are responsible for the invasion of the susceptible cells. The
furin cleavage of p62 precursor leads to the formation of E3 and E2. E2 helps in receptor
binding during invasion and E1 aids in membrane fusion. nsP1 is a membrane-associated
protein that bears methyl transferase and guanyl transferase activities and is involved in the
capping of positive RNA genomes. nsP2 is made up of three domains and contains a
nuclear localization sequence that helps in its translocation into the nucleus. nsP4 contains
RNA-dependent-RNA polymerase and is involved in genome replication and transcription,
whereas no precise role has been known for nsP3.
1.1.2 Transmission
CHIKV is transmitted through the bites of infected mosquitoes, mostly Aedes (A.)
aegypti and A. albopictus. They are day-biting mosquitoes that are also responsible for
the transmission of dengue virus and Zika virus. Sylvatic transmission cycle between
non-human primates, small mammals, and Aedes mosquitoes has maintained the viral
transmission in Africa, where A. furcifer, A. taylori, A. africanus, and A. luteocephalus
are the principal vectors in forested habitats (Diallo et al, 1999; Jupp et al, 1981; Jupp et
al, 1990; Paterson et al, 1964). Even in the absence of animal reservoirs, outbreaks have
been possible due to heavy rainfall and spillover of the virus from the enzootic forest
cycle to the epizootic woodland cycle. Similarly, a rural outbreak occurs when the
2

number of mosquitoes increases in a naïve area (Peyrefitte et al, 2007; Peyrefitte et al,
2008). In Asia, the virus circulates between mosquitoes and people and can cause an
urban transmission cycle (Weaver, 2006; Weaver and Reisen, 2010). A. aegypti is present
in the tropical and subtropical areas; additionally, A. albopictus is distributed widely in
the temperate areas, causing outbreaks in new regions (Weaver and Reisen, 2010;
Tsetsarkin et al, 2011). A. aegypti is dominant in the South-East Asian region, whereas A.
albopictus is more effective in the Americas, Central Africa, and islands of the Indian
Ocean Region. Both vectors live in close proximity to people with adult females of A.
aegypti resting inside houses and feeding on humans (Ooi and Gubler, 2010).
1.1.3 CHIKV Disease Symptoms
Signs and symptoms of CHIKV disease are similar to dengue fever which can
cause a delay in symptomatic diagnosis. Symptoms develop in most infected people
usually 3-7 days after being bitten by an infected mosquito. Fever (102-105F) and joint
pain are the most common symptoms; but other symptoms include headache, muscle
pain, joint swelling, or rash (CDC, 2018). During the La Reunion outbreak, the most
common symptoms were fever, incapacitating polyarthralgia infecting the lower and
small joints, asthenia, headache, digestive troubles, myalgia, conjunctival hyperemia,
adenopathy, and cutaneous manifestations (Lemant et al, 2008; Economopoulou et al,
2009; Borgherini et al, 2007). Joint pain was sustained in most of the infected adults even
one year after infection. Extreme pain and numbness in more than one joint in fingers,
wrists, elbows, toes, ankles, and knees are common. Some atypical symptoms, like
diarrhea, vomiting, hepatitis, autoimmune neurologic pathologies (Guillain-Barre),
encephalitis or meningoencephalitis, myocarditis, or pericarditis are also present in
3

children, elderly people, and patients with comorbidities (Borgherini et al, 2007).
Abnormalities in the laboratory features included leucopenia, thrombocytopenia,
lymphopenia, increased aspartate aminotransferase and alanine aminotransferase, and
hypocalcemia (Borgherini et al, 2007). Although CHIKV disease has high morbidity with
severe and disabling symptoms, the case fatality rate has been estimated to be only
1:1000 (Lemant et al, 2008). Most of the patients recover within a week, but in some
cases, chronic joint pain can persist. Those at higher risk for severe illness include
newborns, those over 65 years old, and adults with underlying conditions as high blood
pressure, heart disease, or diabetes (Silva et al, 2017). Prior infection with CHIKV
protects a person from further CHIKV infections.
Non-human primates (NHPs) are the natural amplification host for CHIKV and
share significant genetic and physiological homology with humans (Broeckel et al, 2015).
The common clinical presentations among them are acute fever, rash, viremia and
production of type I IFNs (Broeckel et al, 2015). The infectious virus can be recovered
from the spleen, liver, and muscles of NHPs, particularly in cynomolgus macaques, even
after 44 days post infection. Similarly, one study reported symptoms like lethargy,
difficulty of walking, dragging of hind limbs, and reduced weight gain among newborn
and 7 to 10 days old mice inoculated subcutaneously with CHIKV (Ziegler et al, 2008).
The virus persisted in the muscles for several days even after viremia disappeared. Focal
necrosis and inflammation of the skeletal muscle, followed by fibrosis and dystrophic
calcification, even in the joint cartilage was seen, but most of the mice eventually
recovered (Ziegler et al, 2008).
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1.1.4 Immune Responses in Animal Models
The biggest challenge for CHIKV studies is the lack of a good animal model. In
the earlier studies, young albino Swiss mice were used (Carey, 1971), but C57BL/6, ICR,
and CD-1 mice have also been used for their age-dependent susceptibility (Ziegler et al,
2008; Couderc et al, 2008). Newborn and young mice develop lethargy, difficulty in
walking, dragging of hind limbs, and reduced weight gain after infection. The detection
of the virus in the leg muscle is possible for several weeks after infection. Focal necrosis
and inflammation of the skeletal muscles, followed by fibrosis and dystrophic
calcification, are the major histopathological changes (Ziegler et al, 2008). Mice lacking
T and B cells (Rag2-/-) have persistent, high-level viremia with no evidence of
inflammation within infected tissues (Teo et al, 2013). Furthermore, Rag1-/- mice have
long-term persistent levels of CHIKV RNA in infected tissues, joints, and serum,
implicating the adaptive immune response in controlling CHIKV infection (Hawman et
al, 2013). In a previous study in a murine model, it was reported that antibodies against
chikungunya virus were produced at an early phase and were directed against the Cterminus of the viral E2 glycoprotein (Lum et al, 2013).
1.1.5 Human Immune Responses to CHIKV Infection
After CHIKV is transmitted into a human host through a mosquito bite, it
replicates locally in the skin and then disseminates into the liver and joints through the
blood (Das et al, 2010). For the initial 12 days, acute viremia (105-1012 RNA copies/ml of
blood) occurs (Das et al, 2010), after which it gradually resolves, but arthralgia might
persist for months or even years. The actual mechanism for the sequence of events that
occur has been poorly understood, however, during some outbreaks, studies have been
5

performed in the cells and organs involved in viral replication. CHIKV replicates in
human epithelial and endothelial cells, primary fibroblasts, monocyte-derived
macrophages (Sourisseau et al, 2007), and human satellite cells (Ozden et al, 2007).
Innate immunity plays a central role in the protection of hosts from early viral
infection. It senses the virus and inhibits the process of viral replication. Some conserved
motifs called pathogen-associated molecular patterns (PAMPs) are sensed by the pattern
recognition receptors (PRRs) in the host (O’Neill and Bowie, 2007; Gilliet et al, 2008).
There are several types of PRRs, which include Toll-like receptors (TLRs), C-type lectin
receptors, retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs), nucleotidebinding oligomerization domain-like receptors, and cytosolic DNA sensors, such as
cyclic GMP-AMP synthetase (Goubau et al, 2013). Among them, TLRs in the plasma
membrane or endosomal compartments and RLRs in the cytoplasm (Pichlmair and Reis e
Sousa, 2007; McCartney and Colonna, 2009) are mainly involved in detecting viral RNA
and triggering innate immune responses. Activation of the PRRs due to the presence of
PAMPs leads to the production of type I interferons (IFNs) as shown in Figure 1.1.
During the initial phase of infection, IFNs help with controlling viral replication and
pathogenesis. They activate the transcription of interferon-stimulated genes (ISGs) which
contain promoter elements that are sensitive to Interferon regulatory factors (IRFs) (Ng et
al, 2009; Grandvaux et al, 2002). In vitro studies with human peripheral blood
mononuclear cells (PBMCs) and mouse dendritic cells (DCs) suggest that rather than
direct interaction between CHIKV and PRRs on hematopoietic cells, the production of
type I IFNs following CHIKV infection is due to the cooperation between multiple host
adaptor molecules on CHIKV-infected fibroblasts (Schilte et al, 2010). Activation of this
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type I IFN response was due to CARD adaptor inducing IFN (CARDIF, also known as
MAVS) acting downstream of MDA5 and RIG-I (Schilte et al, 2010; White et al, 2011).
Further, an adaptor for multiple TLRs and IL-1, myeloid differentiation primary
response protein 88 (Myd88), also may control CHIKV replication through type I IFN
signaling (Shabman et al, 2007).

Figure 1.1 Interferon signaling pathway (Schneider et al, 2014)
Different PRRs in the cells may sense the presence of viral PAMPs, which leads to the activation of IRFs and the production of
different types of IFNs. IFNs signaling leads to the production of different ISGs through JAK-STAT signaling pathway.

Activation and proliferation of CD8+ T cells occur in the early stage of acute
infection, whereas in the later stage, CD4 T cell response and the production of antiinflammatory proteins IL-1RA and IL-2RA occurs (Wauquier et al, 2011). Similarly,
CHIKV infection also leads to a strong inflammatory response by the production of IL16, MCP-1, IP-10, and MIP-1α. Similarly, the production of proinflammatory MIF, MIP1b, SDF-1a, IL-6, and IL-8 signals the end of the acute phase (Sourisseau et al, 2007). IL4 and IL-10 are the B cell promoting cytokines that are upregulated after the onset of
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symptoms and enhance the production of CHIKV-specific IgG (Kam et al, 2012). It has
also been reported that CD95-based apoptosis of CD4+ lymphocytes might cause
lymphopenia (Wauquier et al, 2011).
1.2 Interleukin-17A
IL-17A is a founding member of the IL-17 family with six cytokines, IL-17A
through IL-17F (Agarwal and Gurney, 2002). It has a molecular weight of approximately
17kDa and three potential N-linked glycosylation sites. It is a pro-inflammatory cytokine
with potent effects on numerous cells of the innate immune system, particularly the
granulocyte lineage. IL-17F resembles IL-17A most closely, both in terms of homology
and function. It has 58% sequence identity with IL-17A at the protein level (Gaffen et al,
2006), and both bind to the same receptor. In addition, both IL-17A and IL-17F are
produced by the same cell types, and play important roles in neutrophil recruitment,
particularly in the lung (Kolls and Linden, 2004). Moreover, both are demonstrated to
play inflammatory roles in the pathogenesis of cystic fibrosis (McAllister et al, 2005). IL17A and IL-17F are linked on chromosome 6p12 and may be coordinately regulated at
the transcriptional level (Gaffen et al, 2006).
Once being exposed to a pathogen or pathogen-associated molecular patterns
(PAMPs), dendritic cells, monocytes, and macrophages induce IL-23, IL-1β, IL-6, and
transforming growth factor-beta (TGF-β), which further initiate the differentiation and
polarization of naïve CD4+ T cells towards T helper cell type 17 (TH17) subsets
(Veldhoen et al, 2006; Bettelli et al, 2006; Zhou et al, 2007; Mangan et al, 2006). The
primary sources of IL-17 are TH17 cells, which co-produce other cytokines like IL-22,
IL-21, tumor necrosis factor-alpha (TNF-α), and granulocyte macrophage-colony
8

stimulating factor (GM-CSF) (Guglani and Khader, 2010; McGeachy, 2011). Further,
TH17 cells can also co-express GATA binding protein 3 (GATA-3) or T-box
transcription factor (T-bet), which can progress into either IL-4-expressing or interferongamma (IFN-)-expressing TH17 subsets (Evans and Jenner, 2013). During infection,
TH17 cells exhibit substantial plasticity (Das and Khader, 2017) and co-express TH17
cytokines along with other TH1, TH2, and Treg-associated cytokines. IL-17A can also be
produced by innate cells such as γδ T cells (Chien et al, 2013) and group 3 innate
lymphoid cells (iLC3) (Cortez et al, 2015; Ciccia et al, 2015) in response to IL-23 and IL1β production by myeloid cells, and IL-17 producing CD8+ T (TC17) cells (Hamada et al,
2009). After being stimulated by TGF-β, IL-1β, IL-6, IL-23, or alpha-galactoceramide
(Barthelemy et al, 2016), IL-17A can be produced by neutrophils (Taylor et al, 2014; Bi
et al, 2014), invariant natural killer T (iNKT) cells (Monteiro et al, 2013), innate TH17
cells (iTH17) (Massot et al, 2014), and natural killer (NK) cells (Passos et al, 2010). IL17A mediated protection against pathogens occurs through the induction of chemokines
and cytokines and through the downstream recruitment of neutrophils (McCarthy et al,
2014; Lubberts et al, 2005). IL-17A can either act alone or in combination with TNF-α
and IL-22 and induce neutrophil-recruiting chemokines, such as granulocyte-colonystimulating factor (G-CSF) and C-X-C motif chemokine ligand 1 (CXCL1), and regulate
neutrophil-mediated destruction of pathogens (Dixon et al, 2016).
1.2.1 Role of IL-17A in infectious diseases
IL-17A has been shown to facilitate WNV clearance from mouse brains by
promoting CD8+ T-cell cytotoxicity (Acharya et al, 2017) and by inhibiting replication of
HSV by increasing IFN-γ+ Th1 cell immunity (Bagri et al, 2017), whereas IL-17A
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signaling can also support infections of adenovirus by expressing high levels of IL-7R
and RORγt in mouse liver cells (Hou et al, 2013; Jie et al, 2014). In addition, IL-17A has
been suggested to facilitate the infection of coxsackievirus B3 by decreasing splenic
CD8+ T cell numbers and cardiac IFN-γ production (Yuan et al, 2010) and to facilitate
Theiler’s murine encephalomyelitis virus infection by up-regulating anti-apoptotic
molecules (Hou et al, 2009; Hou et al, 2014). During bacterial infections, IL-17A was
reported to be involved in the induction of anti-microbial molecules and neutrophil
recruitment at the site of infection. A protective role of IL-17A has been shown during
extracellular bacterial infection of Klebsiella pneumonia (Ye et al, 2001), Citrobacter
rodentium (Collins et al, 2014), Staphylococcus aureus (Murphy et al, 2014), and
Bordetella pertussis (Warfel and Merkel, 2013) and during infection with intracellular
pathogens such as Listeria monocytogenes (Sheridan et al, 2013), Mycoplasma
pneumonia (Way et al, 2013), Legionella pneumophila (Kimizuka et al, 2011; Cai et al,
2016), Salmonella typhimurium (Keestra et al, 2011), Chlamydia muridarum (O’Meara et
al, 2014), Francisella tularensis (Skyberg et al, 2013), and Mycobacterium tuberculosis
(Monin et al, 2015). Studies in parasites have reported that Th17 cells mediate host
defense against Trypanosoma cruzi (Erdmann et al, 2013), Toxoplasma gondii
(Peckhman et al, 2014), Leishmania braziliensis (de Oliveira and Brodskyn, 2012), and
Echinococcus granulosus (Mezioug and Touil-Boukoffa, 2012) infections. Further,
during fungal infection, IL-17A is immunologically important for protecting host against
Candida albicans (Trautwein-Weidner et al, 2015), Cryptococcus neoformans (Murdock
et al, 2014), Pneumocystis carinii (Rudner et al, 2007), and Aspergillus fumigatus
(Guerra et al, 2017).
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1.2.2 IL-17A and CHIKV pathogenesis
Joint pain and joint inflammation are the most distinct features of CHIKV
infection. It has been previously reported that during CHIKV infection, the serum IL-17A
levels in patients with arthritis were higher than the ones without arthritis (Kashyap et al,
2014; Cavalcanti et al, 2019). In addition, IL-17A is a proinflammatory cytokine, and
strong associations between IL-17A levels and swollen joint counts have been identified
(Cavalcanti et al, 2019; Lubberts, 2015). These studies suggest that IL-17A might play an
important role in the pathogenesis of CHIKV, however, its detailed role has not been
characterized.
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- SIGNIFICANCE, HYPOTHESIS, AND INNOVATION
2.1 Significance
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that can cause mild
to severe disease in humans. The most common symptoms are fever and joint pain. Other
symptoms may include headache, muscle pain, joint swelling, or rash. Though CHIKV
pathogenesis has been intensively studied, it is still not well understood, and there is no
vaccine to prevent or medicine to treat CHIKV infection. IL-17A is a major cytokine in
the IL-17 family, which regulates the expression of inflammatory cytokines and
chemokines, activation and recruitment of leukocytes, and production of antibodies. Its
role has been studied during inflammation, allergic and autoimmune diseases,
malignancies, and infections. Further, the roles of interferons (IFNs) to control viral
replication during infection forms the basis of innate immunity. In this study, we studied
the role of IL-17A during CHIKV infection and observed that IL-17A facilitates CHIKV
replication by inhibiting IFN-2. The role of IL-17A in inhibiting IFN-2 during viral
infection is novel, and this may lead to new therapeutic strategies. Besides, this relation
between IL-17A and IFNs may have broad implications in studying the pathogenesis of
different viral infections.
2.2 Hypothesis
Many studies have been performed with CHIKV in the last decade, but the
pathogenesis and host immune response during infection is still not fully understood.
Some patients suffer from chronic joint pains after infection, the reason for which is still
unclear. IL-17A is a major member of the IL-17 family and is involved in a variety of
immune functions, such as the expression of cytokines and chemokines involved in
12

inflammation, activation and recruitment of leukocytes, and production of antibodies (Gu
et al, 2013; Song and Qian, 2013). Further, its role has also been studied as a mediator of
inflammation in allergic and autoimmune diseases, malignancies and infections (van den
Berg and Miossec, 2009; Conti et al, 2009, Hamada et al, 2008; Happel et al, 2005;
Huang et al, 2004; Lin et al, 2009; Martin-Orozco and Dong, 2009; McFarland and
Martin, 2007; Murugaiyan and Saha, 2009; Newcomb and Peebles, 2013; Raychaudhuri,
2013; Rudner et al, 2007; Shibata et al, 2007; Witowski et al, 2004; Ye et al, 2001; Zepp
et al, 2011; Zhang et al, 2009). As described in the introduction, IL-17A can have
beneficial or harmful effects during viral infections. However, the role of IL-17A has not
been studied during CHIKV infection. Both CHIKV and IL-17A have been implicated in
inflammation, and there is strong evidence suggesting the possible involvement of IL17A during CHIKV infection. Therefore, we hypothesized that the signaling of IL-17A
supports the viral replication during CHIKV infection. To test this hypothesis, we studied
the functional role of IL-17A during CHIKV infection under the following specific aims.
Specific Aim 1: Study the expression of IL-17A during CHIKV infection in vitro
and in vivo. It has been previously reported that among different cytokines and
chemokines triggered during CHIKV infection, IL-17A is also upregulated during acute
infections or neurological cases (Kashyap et al, 2014; Tanabe et al, 2019). Further, the
chronic effects during CHIKV infection are related to joint swelling and arthritis in
humans. On the other hand, IL-17A is also involved in inflammation as it has been
reported in the synovial fluids and synovium of rheumatoid arthritis (RA) patients
(Chabaud et al, 1998). In studies involving mouse models of RA, IL-17A has been
reported as a key factor involved in the progression of disease (Murphy et al, 2003;
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Nakae et al, 2003; Nakae et al, 2003; Lubberts et al, 2004; Ruddy et al, 2004). So, we
asked if CHIKV infection induces IL-17A production.
Specific Aim 2: Study the role of IL-17A during CHIKV infection in a mouse
model. The role of IL-17A during infection has been studied for different viruses, and it
may provide beneficial or harmful effects to the host. To answer this question during
CHIKV infection, we used a mouse model of CHIKV infection and compared the footpad
swelling and the viral burden in blood and infected footpads among IL-17A deficient
(Il17a-/-), IL-17A receptor deficient (Il17ra-/-), and WT control mice.
Specific Aim 3: Study the effect of IL-17A in immune functions during CHIKV
infection. Some studies have reported that the effect of IL-17A in the host can be
attributed to controlling the level of viral infections (Acharya et al, 2017; Bagri et al,
2017; Hamada et al, 2009; Hou et al, 2009; Hou et al, 2013; Hou et al, 2014; Kohyama et
al, 2007; Mukherjee et al, 2011; Patera et al, 2002; Wang et al, 2016; Yeh et al, 2010;
Yuan et al, 2010) or viral infection-induced organ pathology (Huang et al, 2015;
Mukherjee et al, 2011; Wang et al, 2011; Xue et al, 2017; Yuan et al, 2010; Zhang et al,
2016). In this aim, we asked how immune functions were controlled by IL-17A during
CHIKV infection.
Specific Aim 4: Study the mechanism of IL-17A mediated CHIKV pathogenesis.
From Aim 3, we identified the role of IL-17A in inhibiting IFN-2 during CHIKV
infection. Under Aim 4, we studied the mechanism leading to the production of IFN-2
in the presence of IL-17A during CHIKV infection, and we further studied the role of
IFN during CHIKV infection by using type I interferon receptor deficient (Ifnar1-/-) mice.
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2.3 Innovation

IL-17A is a pro-inflammatory cytokine that exerts diverse immune functions,
including host defense from infection, tissue remodeling and repair, regulation of
immune cell homing and inflammation, and cancer progression. The role of IL-17A
during viral infections is not clear; it is beneficial to the host during WNV infection but
harmful during adenovirus and TMEV infections. However, the role of IL-17A during
CHIKV pathogenesis has not been characterized. In this study, we assessed the role of
IL-17A during CHIKV infection and discovered that the presence of IL-17A makes mice
more susceptible to CHIKV infection and promotes CHIKV-induced inflammation in
mice. Further, we also found a deficiency in IFN-2 expression by IL-17A during
CHIKV infection. IFNs play a central role in the innate immune response and are
important in controlling viral infections. They lead to the transcription of hundreds of
interferon-stimulated genes that have antiviral, antimicrobial, antiproliferative, and
immunomodulatory effects in cells. Inhibition of IFNs can provide a replicative
advantage to the viruses in the cells and may lead to severe disease. In this study, by
using a mouse model of CHIKV infection, we discovered a novel and previously
unappreciated function of IL-17A in CHIKV pathogenesis through inhibition of IFN-2.
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– EXPERIMENTAL APPROACHES
3.1 Ethics statement and Biosafety
All the experimental procedures including animals in this study were reviewed
and approved by the Institutional Animal Care and Use Committees at The University of
Southern Mississippi (USM). Experiments and animal studies involving live CHIKV
were performed by certified personnel in Biosafety Level 3 (BSL-3) laboratories
following the biosafety protocols approved by the USM Institutional Biosafety
Committee.
3.2 Viruses
CHIKV (LR OPY1 2006 strain) was provided by Dr. Robert B. Tesh, University
of Texas Medical Branch. A single passage of parental virus was propagated in Vero
cells (ATCC CCL-81) and used as viral stock for this study. The viral stocks were titrated
in Vero cells by plaque assay as previously described (Bai et al, 2005).
3.3 Cells
Vero cells, NIH3T3 cells (ATCC CRL-1658) and Raw 264.7 cells (ATCC TIB71) were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Life
Technologies) containing 1% L-glutamine, 1% penicillin/streptomycin, and 10% fetal
bovine serum (FBS). Saos2 cells (ATCC HTB-85) were cultured in McCoy’s 5A medium
(ATCC 30-2007) supplemented with 15% FBS. All cells were kept in an incubator at
37°C with 5% CO2 and relative humidity of about 95%. Mouse bone-marrow derived
macrophages (BMDM) and dendritic cells (BMDC) were prepared according to previous
publications (Bai et al, 2009; Acharya et al, 2015; Paul et al, 2017).
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3.4 Mice
WT mice (C57BL/6J) and the breeding pairs of Ifnar1-/- mice were purchased
from the Jackson Laboratory (Bar Harbor, ME). Il17a-/- mice breeding pairs (C57BL/6J
background) were provided by Dr. Richard A. Flavell at the Yale University School of
Medicine, and Il17ra-/- mice breeding pairs in C57BL/6J background were provided from
Dr. Sarah Gaffen at the University of Pittsburgh. All the breeding pairs and their pups
were kept in a clean room until ready to use, and the infection experiments were carried
out in the BSL-3 animal facility at USM.
Seven to eight weeks old, sex-matched WT control, Il17a-/-, Il17ra-/- and Ifnar1-/mice were subcutaneously injected on the ventral side of the left hind footpad toward the
ankle with 1  105 PFU of CHIKV in 50 µl phosphate buffer saline (PBS), as mentioned
in the previous publications (Bai et al, 2009; Gardner et al, 2010). Starting from the day
of infection (day 0) to 12 days post-infection (p.i.), the thickness and width of the perimetatarsal area of the infected feet were measured daily using a digital caliper (Electron
Microscopy Science). The relative increase in footpad swelling was calculated and
expressed in comparison to pre-infection as previously described (Acharya et al, 2015;
Paul et al, 2017; Gardner et al, 2010; Teng et al, 2012). Blood samples were collected in
0.5M EDTA by retro-orbital bleeding, and the viral RNA was quantified by RT-QPCR.
Some mice were sacrificed for infected footpad collection on d1 p.i. for viral
measurement as shown in Figure 3.1. On d6 p.i., some infected footpads were collected
for flow cytometric analysis of the immune cells and histological analysis of the infected
area by H & E staining.
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Figure 3.1 Flow chart for the mouse studies.
Mice were infected with CHIKV subcutaneously, and blood was collected on days 1 and 2 p.i. for viral measurement. Some mice
were sacrificed for footpad collection on d1 p.i. for viral measurement and d6 p.i. for histology and flow cytometry. The footpad
swelling of mice was measured daily from d0 to d12 p.i., and at the end of experiments, all the mice were sacrificed on d12 p.i.

3.5 Quantitative PCR (QPCR)
Total RNA was converted into the first-strand complementary DNA (cDNA)
using iSCRIPTTM cDNA synthesis kit (Bio-Rad). QPCR assays were performed in a CFX
Connect Real-Time System (Bio-Rad) using SYBR Green supermix (Bio-Rad) for the
detection of CHIKV-E1 and β-actin. Viral RNA copy numbers were expressed as the
ratio of CHIKV-E1 to cellular β-actin. For cytokine QPCR assays, data were expressed as
relative fold change (RFC) expressed by ΔΔCT method after normalizing to cellular βactin. The primer sequences were designed using NCBI’s primer-designing tool and
synthesized by Integrated DNA Technologies or Invitrogen and are listed in Table 3.1.
Table 3.1 Primer sequences used in this study
Primer
mβ-actin
hβ-actin
mIl17a
hIl17a
CHIKV E1
Ifn-α
Ifn-

Forward 5’-3’
AGA GGG AAA TCG TGC GTG AC
GCG CGG CTA CAG CTT CA
TCT CCA CCG CAA TGA AGA CC
GTG GACT CTG GGA GGC AAA GT
TCC GGG AAG CTG AGA TAG AA
AGG ACA GGA AGG ATT TTG GA
CGT TCC TGC TGT GCT TCT CC

Reverse 5’-3’
CAA TAG TGA TGA TGA CCT GGC CGT
TCT CCT TAA TGT CAC GCA CGA T
TTT CCC TCC GCA TTG ACA CA
GAT CTC TTG CTG GAT GGG GA
ACG CCG GGT AGT TGA CTA TG
GCT GCT GAT GGA GGT CAT T
TCT TGG AGC TGG AGC TGC TT
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Table 3.1 Continued…
Ifn-
mIRF-3
mIRF-5
mIRF-7
mSTAT-1
Rig-I
Mda5
Myd88
Tlr-3
Tlr-9
Il-12
Cxcl2
Cxcr3
Ifn-α1
Ifn-α2
Ifn-α4
Ifn-α5
Ifn-α6
Ifn-α7
Ifn-α8
Ifn-α9
Ifn-α12
Ifn-α13
Ifn-α14

CAT TGA AAG CCT AGA AAG TCT
G
CGT ACA TCT GGG TGC CTC TC

CTC ATG AAT GCA TCC TTT TTC G

AAT ACC CCA CCA CCT TTT GA
CTG GAG CCA TGG GTA TGC A
GCT GAA TTC CAT CGA GCT CAC
TCA
TTG CTG AGT GCA ATC TCG TC
CGA TCC GAA TGA TTG ATG CA
CAC TCG CAG TTT GTT GGA TG
TTG TCT TCT GCA CGA ACC TG
ACT GAG CAC CCC TGA TTC TA
CCT TGC ATC TGG CGT CTA CA
GCG CCC AGA CAG AAG TCA TA
AGC CCT CAC CTG CAT AGT TG
AGA GAA GAA ACA CAG CCC CTG
TTA GGA AGC AAG GGG AGG GT
TTG CTG GCA AGA CTG AGT GA
GAG CCC TGT CTT CCT CAG TT
GGA CGA GTG AGT CCT GAG AC
GGA GGT GGT CAG AGC AGA AAT
TGG AGA GAC CTC CCT GGA CT
CAG CAG ATC CTG ACC CTC TTC
CAC TGA CCC TCA CTG CTC AA
ACT TGC TGG CAA GAC TGA GC
GCA GAT CCT GAC CCT CTT CAC

TTG AGA TCC GGG TTT GAG AT
AAG CAC AAG CCG AGA CTG CT
AAA CTC GAG CTC AGC TGC CAG ACT
TCC
GTA TGC GGT GAA CCG TCT TT
AGT TGG TCA TTG CAA CTG CT
TCT GGA AGT CAC ATT CCT TGC
CGC AAC GCA AGG ATT TTA TT
AGA TTA GTC AGC GGC AGG AA
TTC TCT GGC CGT CAC CA
CAG TTA GCC TTG CCT TTG TTC A
TTG AGG CGC TGA TCG TAG TT
GAG ATA TGA GCA GAG AGG TAC AGT
AGC ATC ACG AGG AAA GCA CA
GAG AAG AAT TGC TCA AGA TTG CTG A
TGA TCG CTC AAG ATT GCT GAA AC
ATG GTG CAG ATA CAA AAG TGG C
CAG TGT CCT AAT CCT GGA GAT GG
ATG GTG CAG ATA CAA AAG TGG CT
CAG TTC CTT CAT CCC GAC C
TGC AGA GAG ACA TGA CAT TGC
TCA GTT TTG CTG AAA CAT CTA GGC
AGG TGC CTG TAT CTC TAC CTG C

ACC TCG AAC TCC CAT TGT TCC

3.6 Plaque Assay
Vero cells were plated in 6-welled plates at a density of 6  105 cells per well and
incubated overnight. Cell culture supernatant or mouse blood samples were applied to the
wells and incubated for 1 h at 37°C with 5% CO2. After incubation, the sample
containing medium was removed, and the cells were covered with an overlay medium
containing 1% SeaPlaque agarose (Lonza). The plates were incubated for 2 to 3 days
until the plaques were observed. Plaques were stained with Neutral Red and counted.
3.7 Flow cytometry
For flow cytometric analysis of footpad immune cells, the infected footpad tissues
were collected to prepare single-cell suspension as previously described protocol (Akitsu
and Iwakura, 2016). The infected footpads were chopped in small pieces and incubated
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for 1 hour at 37°C in Digestion medium containing hyaluronidase and collagenase type
VIII. The footpad cells were collected after filtering the mixture with 70µm strainer.
Viral RNA was quantified from the footpad cells by RT-QPCR. For flow cytometry, the
footpad cells were fixed in 2% paraformaldehyde (Electron Microscopy Science) for 15
minutes at room temperature (RT). The cells were then washed and blocked with Fc
block for 30 minutes at RT. After washing, the cells were probed with mouse monoclonal
anti-CD45, CD4, CD8, CD11b, and Ly6G antibodies (BD BioSciences or eBioscience)
and incubated for 1 hour at RT. The cells were then washed twice and resuspended in
staining buffer and analyzed in a BD LSRFortessa (BD Biosciences) using FlowJo
(Version 10.4).
3.8 Histology
The infected and control mouse footpads were collected on day 6 p.i. After
fixation overnight in 4% PFA, the footpads were decalcified in 10% EDTA for 10 days.
Tissues were then dehydrated, paraffin embedded, and sectioned (10 µm) using a
microtome (American Optical Spencer 820). The sectioned tissue slides were stained
with hematoxylin and eosin (H&E), and images were acquired using a bright-field
microscope (Olympus BH2).
3.9 ELISA and Immunoblotting
IL-17A and IFN-α2 in the cell culture supernatants of CHIKV-infected NIH3T3
cells were measured by using a commercial ELISA kit (Abcam) following the
manufacturer’s instruction. NIH3T3 cells were infected with CHIKV at 1 MOI in the
presence of recombinant IL-17A. After 24 h, the cells were lysed in Laemmli sample
buffer (Bio-Rad), and the proteins were separated by 10% SDS-polyacrylamide gel
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electrophoresis and transferred to a nitrocellulose membrane (Bio-Rad). The membrane
was blocked in 5% milk in Tris-buffered saline with Tween 20 (TBS-T) for 1h at RT and
probed with mouse specific Rabbit primary antibody (Phospho-IRF-7, Cell Signaling;
Phospho-IRF-5, Invitrogen; GAPDH, Abcam) in the ratio 1:1000 at 4°C overnight in a
rocker. After washing with TBS-T, horseradish peroxidase conjugated secondary
antibody (Goat pAb to Rabbit IgG, Abcam; 1:5000) was added for 1 hour at RT. The
membranes were washed and developed using SuperSignal West Pico
Chemiluminiscence Substrate (Thermo Scientific), and images were acquired using a
ChemiDoc MP system (Bio-Rad). Quantification of blot was performed by ImageLab.
3.10 Statistical analyses
Data analysis was done by using either Student’s t-test or one-way analysis of
variance (ANOVA) wherever applicable in GraphPad Prism software (version 6.0), p <
0.05 being considered statistically significant.
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– RESULTS
4.1 CHIKV induces the expression of Il-17a in vitro and in vivo
To test our hypothesis if IL-17A might play a crucial role in the pathogenesis of
CHIKV infection, we measured the expression of Il-17a in CHIKV-infected mouse and
human cells in vitro. Mouse fibroblasts (NIH3T3 cells) and human bone epithelial cells
(Saos2 cells) were infected with CHIKV (MOI 0.1, 0.5, and 1). The cells were collected
at 24 h post-infection (p.i.) to measure transcripts of Il-17a and cellular β-actin, a
housekeeping gene by a reverse-transcription quantitative PCR (QPCR). The results
showed that the expression of Il-17a was upregulated in both CHIKV-infected NIH3T3
cells (Figure 4.1A) and Saos2 cells (Figure 4.1B) in a dose-dependent manner. To relate
these results in vivo, we infected C57BL/6J wild-type (WT) mice with CHIKV via
footpad, and the blood samples were collected on days (D) 1 and 2 p.i. Similar to the in
vitro results, Il-17a transcript levels were upregulated after the CHIKV infection (Figure
4.1C). These results demonstrate that CHIKV infection upregulates the expression of Il17a in both human and mouse cells.
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Figure 4.1 CHIKV infection induces the expression of Il17a in mouse and human cells.
Mouse fibroblast NIH3T3 cells and human bone epithelial Saos2 cells were infected with CHIKV with different MOIs for 24 h. The
relative expression of Il17a was measured by QPCR and expressed as Relative Fold Changes (RFC) after normalization to mouse or
human β-actin, respectively. (A) RFC of mouse Il17a in NIH3T3 cells; (B) RFC of human Il17a in Saos2 cells. WT (C57BL/6J) mice
(7 to 8 weeks old) were inoculated with CHIKV (1×105 PFU) or vehicle control (PBS) via footpad, and blood was collected on days 1
and 2 p.i. (C) RFC of mouse Il17a was compared with the control mice after normalized to β-actin (Vehicle control, n = 7, and
infected, n = 11). The results in (A) and (B) were compared using one-way ANOVA followed by Tukey’s test (*, **, ***, and ****
denote p < 0.05, p < 0.01, p < 0.001, and p < 0.0001, respectively). The results in (C) were analyzed using a two-tailed student’s t-test.
These results represent two independent experiments with the same trend. The error bars are the standard errors of the mean (SEM).
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4.2 Il17a-/- and Il17ra-/- mice are more resistant to CHIKV infection
To investigate the role of IL-17A in CHIKV infection, we infected 7 to 8 weeks
old, sex-matched WT, IL-17A-deficient (Il17a-/-), and IL-17A receptor-deficient (Il17ra-/) mice with 1×105 PFU of CHIKV via footpad, as described in the previous reports (Teo
et al, 2013; Acharya et al, 2015). Blood was collected on D1 and 2 p.i., and the viremia
was measured by both QPCR and plaque assay. The QPCR results showed a 3-fold mean
reduction of CHIKVE1 on D1 p.i. in the Il17a-/- and Il17ra-/- mice compared to WT mice
(Figure 4.2A), and the viral RNA was mostly cleared from the blood on D2 p.i. The
plaque assay results of the D1 sample also showed less infectious viruses in the blood of
the knockout mice (Figure 4.2B). After inoculation, the viruses replicate in the footpad
tissues initially. To assess the viral load in the infected footpad, we sacrificed some of the
mice and collected the footpad tissues on D1 p.i. and performed the QPCR analysis.
Consistent with the viremia, there was an approximately 2-fold reduction in CHIKVE1
RNA in the foot tissues of Il17a-/- and Il17ra-/- mice compared to the WT controls (Figure
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Figure 4.2 Il17a-/- and Il17ra-/- mice are more resistant to CHIKV infection.
Seven to eight weeks old WT, Il17a-/- and Il17ra-/- mice were infected with 1×105 PFU of CHIKV via footpad. (A) Blood was
collected on days 1 and 2 p.i., and QPCR was performed to measure the viral burden as the ratio of CHIKV-E1 to β-actin transcripts.
The ratios of viral loads were compared between WT (n = 22) and Il17a-/- (n = 17) or Il17ra-/- (n = 16) mice. (B) CHIKV plaque assay
was performed to measure the viral load in the blood samples on D1. (C) Infected footpads were collected on D1 p.i., and the viral
burden was quantified by QPCR after normalized to β-actin. The results represent three independent experiments analyzed by a twotailed Student t-test, (*, ** and **** denote p < 0.05, p < 0.01, and p < 0.0001 respectively, when compared to WT controls).
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4.3 IL-17A promotes CHIKV-induced inflammation in mice
Following CHIKV infection, viral inoculated footpads usually swell between D2
and D12 p.i. in adult WT C57BL/6J mice (Acharya et al, 2015; Morrison et al, 2011). We
measured the relative increase of the footpad swelling in CHIKV-infected WT, Il17a-/and Il17ra-/- mice daily for 12 days p.i. The swelling data indicated that Il17a-/- and
Il17ra-/- mice had less severe inflammation in the inoculated footpads compared to WT
mice (Figure 4.3A). To further confirm this phenotype, we performed histological and
flow cytometric analysis with the footpad tissues on D6 p.i. The histology results showed
that the footpads of Il17a-/- and Il17ra-/- mice had less severe swelling and tissue damage
compared to that of WT mice (Figure 4.3B). In addition, the flow cytometric analysis
demonstrated that the footpad tissue-infiltrated neutrophils (CD45+CD11b+Ly6G+) were
significantly reduced in the Il17ra-/- mice when compared to WT mice (p < 0.05), while
the difference is not statistically significant (p > 0.05) with CD4 T cells
(CD45+CD3+CD4+), CD8 T cells (CD45+CD3+CD8+), and monocytes (CD45+CD11b+)
(Figure 4.3C). Together, these results suggest that IL-17A signaling promotes CHIKV
replication and enhances CHIKV-induced footpad inflammation in mice.
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Figure 4.3 IL-17A promotes CHIKV-induced inflammation in mice.
(A) Swelling of injected footpads (peri-metatarsal area) of mice is presented as a relative increase in swelling that was calculated by
measuring the thickness and width of an inoculated footpad. (B) Representative H&E stained histological images (10×, upper row and
20×, lower row) of peri-metatarsal area of the inoculated foot tissue (n= 5 mice/group) on D6 p.i.. The layer of epidermis (a) and
dermis (b) are labeled. (C) Seven to 8 weeks old WT and Il17ra-/- mice were infected with 1×105 PFU of CHIKV via footpad. Footpad
cells were isolated at D6 p.i. and quantified by flow cytometry after probing with antibodies against CD45, CD4, CD8, CD11b, and
Ly6G. The cell counts for positive cells within the gated population are shown for WT and Il17ra-/- mice. The results (A) represent
three independent experiments analyzed by a two-tailed Student t-test. The cell count data (C) were compared by two-tailed Student’s
t-test (* denotes p < 0.05, when compared to WT controls).

4.4 Ifn-α2 is specifically inhibited by IL-17A during CHIKV infection
Considering that the CHIKV burden in the blood and footpad tissues is
significantly reduced in Il17a-/- and Il17ra-/- mice on D1 p.i., indicating that IL-17A
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signaling could inhibit the antiviral innate responses, we evaluated the expression of a set
of antiviral genes in the blood of CHIKV-infected Il17ra-/- mice by QPCR analysis.
Interestingly, we found that among all the tested genes (Ifn-α, Ifn-, Ifn-, Rig-I, Mda-5,
Myd88, Tlr3, Tlr9, Il-12, Cxcl2, and Cxcr3), the expression of Ifn-α was significantly
increased (Figure 4.4A).
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Figure 4.4 Ifn-α2 is specifically inhibited by IL-17A during CHIKV infection.
(A) Seven to eight weeks old WT and Il17ra-/- mice were infected with 1×105 PFU of CHIKV via footpad. Blood was collected on day
1 post-infection, and the transcript level of different genes was measured and normalized to β-actin mRNA. (B) NIH3T3 cells were
infected with CHIKV (1 MOI) and treated with different concentrations of IL-17A for 24h. The expression levels of different subtypes
of Ifn-α were measured and normalized to cellular β-actin mRNA. The data represent the results of at least two independent
experiments performed in triplicates and analyzed by one-way ANOVA followed by Turkey’s test, (*, **, and *** denote p < 0.05, p
< 0.01, and p < 0.001 respectively, when compared to untreated control).
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There are 14 known Ifn-α subtypes in mice, and we tested which Ifn-α subtype was
inhibited by IL-17A during CHIKV infection. Interestingly, of 11 tested Ifn-α subtypes
only the transcripts of Ifn-α2 were significantly inhibited in NIH3T3 cells during CHIKV
infection (Figure 4.4B).
4.5 CHIKV induces expression of Ifn-α2 in cells and mice blood
After knowing that Ifn-α2 was specifically inhibited by IL-17A during CHIKV
infection, to further validate these results, we first confirmed that the expression of Ifn-α2
was induced by CHIKV infection in NIH3T3, Saos2 cells, and mice (Figure 4.5A - C).
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Figure 4.5 CHIKV induces expression of Ifn-α2 in cells and mouse blood.
(A) NIH3T3 and (B) Saos2 cells were infected with CHIKV for 24 hours, and the transcript level of Ifn-α2 was measured and
normalized to β-actin mRNA. (C) Seven to eight weeks old WT mice were infected with 1×105 PFU of CHIKV via footpad. Blood
was collected on days 1 and 2 p.i., and the levels of Ifn-α2 were compared to the blood in uninfected WT mice. The data represent the
results of at least two independent experiments performed in triplicates and analyzed by one-way ANOVA followed by Turkey’s test,
(*, **, and *** denote p < 0.05, p < 0.01, and p < 0.001 respectively, when compared to untreated control).

4.6 IL-17A inhibits the expression of Ifn-α2 in different cells during CHIKV
infection
We next tested if the expression of Ifn-α2 in NIH3T3 cells could be inhibited by
recombinant mouse IL-17A (rIL-17A) during CHIKV infection. Both QPCR and ELISA
results indicated that rIL-17A treatment suppressed the expression of Ifn-α2 (Figure 4.6A
and B). Consistently, this phenotype was also confirmed in other types of cells, i.e. Raw
264.7 cells, mouse bone-marrow derived macrophages (BMDM), and bone-marrow
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derived dendritic cells (BMDC), suggesting this is not a cell type-specific effect (Figure
4.6C - H).
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Figure 4.6 IL-17A inhibits the expression of Ifn-α2 in different cells during CHIKV
infection.
(A) NIH3T3 cells were infected with CHIKV (MOI = 1) and treated with different concentrations of rIL-17A for 24 and 48 hours. The
expression of Ifn-α2 was measured by QPCR and normalized to cellular β-actin mRNA. (B) The protein level of IFN-α2 was
measured by ELISA in NIH3T3 cells infected with CHIKV and treated with different concentrations of rIL-17A. Raw 264.7 cells
were infected with CHIKV (MOI = 1) in the presence of different concentrations of rIL-17A and incubated for 24 and 48 h. The
mRNA level (C) and protein level (D) of IFN-α2 was measured. Mouse bone-marrow derived-macrophages (E and F) and dendritic
cells (G and H) were infected with CHIKV (MOI = 1) for 48 h in the presence of rIL-17A (100 ng/ml). The level of Ifn-α2 was
measured by QPCR normalized to cellular β-actin mRNA and ELISA. The data represent the results of at least two independent
experiments performed in triplicates and analyzed by one-way ANOVA followed by Turkey’s test, (*, **, and *** denote p < 0.05, p
< 0.01, and p < 0.001 respectively, when compared to untreated control).
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4.7 IL-17A does not inhibit the expression of Ifn-α2 during WNV and ZIKV
infection in vitro
To test if IL-17A also inhibits the expression of Ifn-α2 during other virus
infections, we infected NIH3T3 cells with West Nile virus (WNV) or Zika virus (ZIKV)
in the presence of rIL-17A and measured Ifn-α2 mRNA by QPCR or ELISA.
Interestingly, the results suggested that IL-17A might not restrain IFN-α2 production
during WNV and ZIKV infections (Figure 4.7A - C).
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Figure 4.7 IL-17A does not inhibit the expression of Ifn-α2 during WNV and ZIKV
infection in vitro.
(A) NIH3T3 cells were infected with WNV (MOI = 1) and treated with different concentrations of rIL-17A for 24 and 48 h. The
expression of Ifn-α2 was measured by QPCR and normalized to cellular β-actin mRNA. (B) ELISA results of IFN-α2 in cell medium
of NIH3T3 cells infected with WNV and treated with different concentrations of rIL-17A. (C) NIH3T3 cells were infected with ZIKV
(MOI = 1) for 24 and 48 h in the presence of different concentrations of rIL-17A. The level of Ifn-α2 was measured by QPCR and
normalized to cellular β-actin mRNA. The data represent the results of at least two independent experiments performed in triplicates
and analyzed by one-way ANOVA followed by Turkey’s test.

4.8 IL-17F does not inhibit the expression of Ifn-α2 during CHIKV infection
IL-17F is another member of the IL-17 family and its functions are closely related
to IL-17A, since it shares the same set of receptors IL-17RA and IL-17RC. To test if IL17F has a similar function to IL-17A, we measured the level of Ifn-α2 in NIH3T3 cells
following CHIKV infection in the presence of rIL-17F (Figure 4.8A and B). Our results
demonstrated that IL-17A, but not IL-17F, specifically inhibited the production of IFNα2 in responding to CHIKV infection.
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Figure 4.8 IL-17F does not inhibit the expression of Ifn-α2 during CHIKV infection in
vitro.
(A) NIH3T3 cells were infected with CHIKV (MOI=1) and treated with different concentrations of rIL-17F for 24 and 48 h. (B) The
expression level of Ifn-α2 was compared by normalizing to cellular β-actin mRNA and protein level of IFN-α2 was measured by
ELISA. The data represent the results of at least two independent experiments performed in triplicates and analyzed by one-way
ANOVA followed by Turkey’s test.

4.9 The expression of Ifn-α2 is up-regulated in Il17a-/- and Il17ra-/- mice during
CHIKV infection
We next measured the expression levels of Ifn-α2 in Il17a-/- and Il17ra-/- mice that
lack IL-17A signaling to further determine if IL-17A signaling inhibits the expression of
Ifn-α2 in vivo following CHIKV infection. Indeed, the mRNA level of Ifn-α2 in blood
was significantly increased in both Il17a-/- and Il17ra-/- mice than in WT mice,
confirming the inhibiting role of IL-17A for the expression of Ifn-α2 (Figure 4.9A and
B).
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Figure 4.9 The expression of Ifn-α2 is up-regulated in the blood of Il17a-/- and Il17ra-/mice during CHIKV infection.
WT, Il17a-/- and Il17ra-/- mice were infected with 1×105 PFU of CHIKV via footpad. Blood was collected on D1 and 2 p.i., and the
mRNA level of Ifn-α2 was measured and normalized to β-actin. (A) Ifn-α2 mRNA levels between WT and Il17a-/- mice; and (B) Ifnα2 mRNA levels between WT and Il17ra-/- mice. The data represent the results of at least two independent experiments performed in
triplicates and analyzed by a two-tailed Student t-test (*, **, and *** denote p < 0.05, p < 0.01, and p < 0.001 respectively, when
compared to WT control).

4.10 rIL-17A enhances CHIKV replication in vitro
IL-17A inhibits Ifn-α2 during CHIKV infection, and as a consequence, the
addition of recombinant (r) mouse IL-17A during CHIKV infection significantly
increases viral replication in NIH3T3 cells (Figure 4.10A and B), which may be due to
the reduced antiviral IFN-α2 production. Considering that pre-treatment of the cells with
rIL-17A prior to CHIKV infection may further enhance susceptibility to CHIKV
infection, we pre-treated the NIH-3T3 cells with rIL-17A or rIL-17F at various
concentrations for 24 h, then inoculated with CHIKV, and measured CHIKV genome
copies in the cells by QPCR. The QPCR results showed that the treatment of rIL-17A,
but not rIL-17F, enhanced CHIKV replication (Figure 4.10C and D), implying that IL17A constrains the production of IFN-α2, thus facilitating CHIKV replication.
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Figure 4.10 rIL-17A enhances CHIKV replication in vitro.
NIH3T3 cells were inoculated with CHIKV (MOI =1) and different concentrations of rIL-17A and kept for 48 h. (A) The ratio of
CHIKVE1 RNA to cellular β-actin was measured by QPCR. (B) Plaque assay was performed to measure the infectious particles in the
cell medium. (C) NIH3T3 cells were pre-incubated with different concentrations of rIL-17A for 24 h, then infected with CHIKV
(MOI = 1) for an additional 48 h. The viral RNA was quantified by QPCR and normalized to cellular β-actin. (D) NIH3T3 cells were
pre-incubated with different concentrations of rIL-17F for 24 h, then infected with CHIKV (MOI = 1), and the viral RNA was
quantified by QPCR and normalized to cellular β-actin. The data represent the results of at least two independent experiments
performed in triplicates and analyzed by one-way ANOVA followed by Turkey’s test, (* and ** denote p < 0.05 and p < 0.01
respectively, when compared to untreated control).

4.11 Ifn-α2 inhibits CHIKV replication in vitro
To confirm the antiviral activities of IFN-α2 inhibiting CHIKV infection in vitro,
we treated NIH-3T3 cells with rIFN-α2 and infected with CHIKV (1 MOI). After 24 h,
the level of virus was inhibited by IFN-α2 by QPCR and plaque assay (Figure 4.11A and
B). In a separate experiment, we tested if the presence of rIL-17A inhibits the antiviral
effects of IFN-α2 by treating NIH-3T3 cells with both rIL-17A and IFN-α2 during
CHIKV infection. The results showed that rIL-17A neutralizes the antiviral effects of
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IFN-α2, whereas the exogenous presence of IFN-α2 could inhibit viral replication even in
the presence of rIL-17A (Figure 4.11C). These results demonstrate that IL-17A signaling
inhibits the production of IFN-α2, and thus facilities CHIKV replication in vitro and in
mice.
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Figure 4.11 Ifn-α2 inhibits CHIKV replication in vitro.
NIH3T3 cells were treated with IFNA2 (100 IU/ml) and CHIKV, 1 MOI for 24 h. (A) The ratio of CHIKVE1 RNA to cellular β-actin
was measured by QPCR. (B) The infectious particles in the cell medium were measured by plaque assay. (C) In another experiment,
NIH3T3 cells were treated with rIL-17A and IFNA2, then infected with CHIKV, 1 MOI for 24 h. The ratio of CHIKVE1 RNA to
cellular β-actin was measured by QPCR. The data represent the results of at least two independent experiments performed in
triplicates and analyzed by a two-tailed Student t-test, (* and *** denote p < 0.05 and p < 0.001 respectively, when compared to
untreated control).

4.12 Neutralization of IL-17A inhibits CHIKV replication in vitro
Considering that the presence of IL-17A inhibits IFN-α2 and facilitates CHIKV
replication, we tested if this can be reversed by neutralizing IL-17A with anti-IL-17A
antibody. We treated NIH-3T3 cells with IL-17A neutralizing antibody and infected with
CHIKV. After 24 hours, the level of Ifn-α2 was increased and CHIKV replication was
reduced by the addition of anti-IL-17A antibody, whereas the expression levels of Ifn-α2
and CHIKV were not altered in the control group, in which the cells were treated with the
anti-flavivirus E antibody (4G2) (Figure 4.12 A and B).
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Figure 4.12 Neutralization of IL-17A decreases CHIKV replication in vitro.
NIH3T3 cells were treated with rIL-17A, anti-IL-17A antibody or a control antibody (100 ng/ml) and infected with CHIKV (1 MOI)
for 24 h. (A) The expression level of Ifn-α2 was compared by normalizing to cellular β-actin mRNA. (B) The ratio of CHIKVE1 RNA
to cellular β-actin was measured by QPCR. The data represent the results of two independent experiments carried out in triplicates,
and analyzed by one-way ANOVA followed by Turkey’s test, (**, *** and **** denote p < 0.01, p < 0.001 and p < 0.0001
respectively, when compared to untreated control).

4.13 IL-17A inhibits the expression of Ifn-α2 via IRF-5 and 7 pathways
We next hypothesized that IL-17A signaling interrupts the signaling pathway(s)
that differentially regulate the expression of Ifn-α subtypes and thus inhibits the
expression of Ifn-α2. Relative amounts of interferon regulatory factor (IRF) genes have
been shown to modulate the differential expression of various IFN-A subtypes during
paramyxovirus infection (Genin et al, 2009). IRF genes have been shown to play
protective roles against CHIKV infection (Rudd et al, 2012). Therefore, we assessed the
role of IL-17A signaling in the expression of IRF genes during CHIKV infection. We
infected NIH3T3 cells with CHIKV in the presence of rIL-17A for QPCR analysis, and
the results showed that the expression of Irf-3, Irf-5 and Irf-7 was inhibited at the
transcriptional levels (Figure 4.13A - C). In addition, the immunoblotting analysis
suggests that IL-17A inhibits the phosphorylation IRF-5 and IRF-7 during CHIKV
infection (Figure 4.13D and E), while the phosphorylation of IRF-3 was not detected.
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Figure 4.13 IL-17A inhibits the expression of Ifn-α2 via IRF-5 and 7 pathways.
NIH3T3 cells were infected with CHIKV (MOI = 1) and simultaneously treated with indicated concentrations of rIL-17A for 48 h.
The transcripts of Irf-3 (A), Irf-5 (B), and Irf-7 (C) were measured by QPCR and expressed as RFC after normalization to cellular βactin mRNA. (D) NIH3T3 cells were infected with CHIKV (MOI = 1) for 24 h in the presence of IL-17A (100 ng/ml) and indicated
proteins in the cell lysates were analyzed by immunoblotting (left) and the ratio of phosphorylated IRF-5 to GAPDH was calculated
by densitometric measurement by using ImageLab (right). (E) The immunoblotting analysis was done similarly for IRF-7 and
GAPDH (left), and the ratio of phosphorylated IRF-7 to GAPDH was calculated by densitometric measurement by using ImageLab
(right). The data (A – C) represent the results of two independent experiments carried out in triplicates, and analyzed by one-way
ANOVA followed by Turkey’s test, (* and ** denote p < 0.05 and p < 0.01 respectively, when compared to untreated control).
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4.14 IL-17A inhibits Irf-5 and Irf-7 in mice during CHIKV infection
Considering IL-17A inhibits the expression and phosphorylation of IRF-5 and
IRF-7 in the cell culture during CHIKV infection, we measured the levels of Irf-5 and Irf7 mRNA in mice blood and footpads following CHIKV infection. Consistent with the
results, the levels of Irf-5 were significantly upregulated in the blood and footpads of
Il17a-/- and Il17ra-/- mice compared to WT control mice (Figure 4.14A - C). A similar
trend was also shown for Irf-7, although the difference was not statistically significant
(Figure 4.14D - F). These results indicate that IL-17A may inhibit the expression of Ifnα2 via IRF-5 and 7 pathways.
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Figure 4.14 IL-17A inhibits Irf-5 and Irf-7 in mice during CHIKV infection.
WT (n = 4), Il17a-/- (n = 10) and Il17ra-/- (n = 10) mice were infected with 1×105 PFU of CHIKV via footpad. Blood was collected on
days 1 and 2 post-infection, and the mRNA levels of Irf-5 were measured and normalized to β-actin mRNA between WT and Il17a-/mice (A), and WT and Il17ra-/- mice (B). Footpads were collected from selected WT (n = 4) and Il17a-/- (n = 4) mice on D1 p.i., and
the mRNA level of Irf-5 was measured and normalized to β-actin mRNA between WT and Il17a-/- mice (C). The mRNA levels of Irf7 were measured in the blood of Il17a-/- mice (D), the blood of Il17ra-/- mice (E), and the footpads of Il17a-/- mice (F). The results
represent three independent experiments analyzed by a two-tailed Student t-test, (*, ** and *** denote p < 0.05, p < 0.01, and p <
0.001 respectively, when compared to WT controls).
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4.15 IL-17A inhibits Isg-49 and Mx1 in mice during CHIKV infection
We next tested if IL-17A signaling inhibits IFN-mediated antiviral responses. We
tested the expression of a set of ISGs (Isg-15, Isg-49, Isg-54, Isg-56, Oas1a, Mx1, Ifitm3,
and bst2) by QPCR in the blood and footpads of WT, Il17a-/- and Il17ra-/- mice following
CHIKV infection. Interestingly, we found that among those tested ISGs, Isg-49 and Mx1
were significantly upregulated in Il17a-/- and Il17ra-/- mice footpads compared to the WT
controls (Figure 4.15A and B). Similar patterns were observed in the blood, although the
differences were not significant (data not shown).
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Figure 4.15 IL-17A inhibits Isg-49 and Mx1 in mice during CHIKV infection.
Footpads were collected from WT (n = 10), Il17a-/- (n = 5) and Il17ra-/- (n = 5) mice on D1 p.i., and the mRNA level of Isg-49 was
measured and normalized to β-actin mRNA (A). The mRNA levels of Mx1 were also measured and normalized to β-actin mRNA in
the footpads of the infected mice (B). The results represent three independent experiments analyzed by a two-tailed Student t-test, (*
and ** denote p < 0.05 and p < 0.01 respectively, when compared to WT controls).

4.16 Neutralization of IL-17A upregulates Irf-5, Irf-7, Isg-49 and Mx1 in cells during
CHIKV infection
To further confirm that IL-17A facilitates CHIKV replication through inhibiting
Irf-5, Irf-7, Isg-49, and Mx1, we tested if this effect is reversed by neutralizing IL-17A
with anti-IL-17A antibody. We treated NIH3T3 cells with IL-17A neutralizing antibody
or a control 4G2 antibody and infected with CHIKV. After 24 hours, the expression
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levels of Irf-5, Irf-7, Isg-49 and Mx1 were upregulated in the presence of IL-17A
neutralizing antibody but were not altered in the control group (Figure 4.16A – D).
Collectively, these results demonstrate that IL-17A signaling inhibits IFN-α2-mediated
antiviral responses during CHIKV infection.
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4.17 Ifnar1-/- mice are more susceptible to CHIKV infection.
As IFN-α2 production is inhibited by IL-17A signaling, and the viral burden as
well as the footpad swelling were reduced in Il17a-/- and Il17ra-/- mice during CHIKV
infection, we wanted to confirm that type I IFN signaling is critical to control CHIKV
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infection in our mouse model. We infected type I IFN receptor-deficient (Ifnar1-/-) and
WT control mice with 1 × 105 PFU of CHIKV. Blood was collected on D1 and 2 p.i., and
the viral RNA was quantified by QPCR. The results indicated that Ifnar1-/- mice
developed a higher viral load than the WT mice (Figure 4.17A). While CHIKV was
mostly cleared from the blood of immunocompetent WT mice by D2 (Figure 4.2A and
4.17A), the viral load on D2 was even higher than D1 in the blood of Ifnar1-/- mice,
suggesting that type I IFN signaling is critical in limiting CHIKV viremia. We also
measured the transcription level of Il-17a in the blood of Ifnar1-/- mice, and the results
showed that the expression of Il-17a was induced in the blood of CHIKV infected mice,
compared with the uninfected controls (Figure 4.17B). While all the WT mice survived
after CHIKV challenge, all the Ifnar1-/- mice succumbed to death within 4 days p.i.
(Figure 4.17C). In addition, Ifnar1-/- mice developed very pronounced footpad swelling
as compared to WT control mice (Figure 4.17D). Together these results confirm that type
I IFN signaling is essential to control CHIKV infection in mice.
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–DISCUSSION
IL-17A signaling has been associated with several inflammatory diseases in
humans, such as rheumatoid arthritis (Kotake et al, 1999; van Bezooijen et al, 1999),
systemic lupus erythematosus (Wong et al, 2000), and Crohn’s disease (Fujino et al,
2003; Yen et al, 2006). Among its diverse functions, IL-17A can regulate the activities of
various other inflammatory cytokines, which include TNF-α, IL-1β, and IFN-γ (Albanesi
et al, 1999; Chabaud et al, 1998; Miossec et al, 2003; Shen et al, 2005). It can also induce
the production of different cytokines, chemokines, acute phase proteins, anti-microbial
peptides, mucins and matrix metalloproteinases (Chang and Dong 2011; Gaffen 2008) to
propagate a series of events leading to neutrophil recruitment, inflammation,
pathogenesis, and host defense. For example, IL-17A signaling has been shown to
upregulate joint destructive factors by stimulating transcriptional NF-κB activity and
expression of IL-1, granulocyte/macrophage colony-stimulating factor (GM-CSF),
prostaglandin E2, IL-6, IL-8, and TNF-α in fibroblasts, endothelial and epithelial cells,
and inducing T cell proliferation (Chabaud et al, 1998; Miossec et al, 2003; Shen et al,
2005; Lubberts et al, 2005; Dong and Nurieva, 2003; Gaffen, 2004; Kolls and Linden,
2004; Koenders et al, 2005; Fossiez et al, 1996; Yao et al, 1995; Katz et al, 2001). In this
study, we report a novel role of IL-17A in inhibiting IFN-α2 expression during CHIKV
infection.
During viral infection, antiviral responses are initiated in the host to inhibit
replication and transmission of the virus, however, the proinflammatory immune
responses can have detrimental effects. Depending on the signaling and subsequent
involvement of different cytokines, IL-17A may play a protective role for the host
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(Acharya et al, 2017; Hou et al, 2013; Bagri et al, 2017; Wang et al, 2016; Hamada et al,
2009; Yeh et al, 2010; Kohyama et al, 2007; Wang et al, 2011; Huang et al, 2015; Zhang
et al, 2016) or mediate inflammatory and pathological responses (Mukherjee et al, 2011;
Yuan et al, 2010; Hou et al, 2009; Hou et al, 2014; Patera et al, 2002; Xue et al, 2017;
Yuan et al, 2010). In humans, CHIKV infection can induce severe inflammatory
responses and chronic arthritis, which is correlated with the increased production of IL17A in patients (Chow et al, 2011; Teng et al, 2015). As such, it is plausible to
hypothesize that IL-17A may play an important role in the pathogenesis of CHIKV. In
this study, we detected a significant up-regulation of Il17a in both human and mouse
cells, and mouse blood and footpads following CHIKV infection (Neupane et al, 2020).
Some studies profiling the cytokines and chemokines triggered during CHIKV infections
in humans have also reported that Il17a is upregulated during acute infection (Tanabe et
al, 2019) or during neurological cases of CHIKV infection (Kashyap et al, 2014).
Interestingly, the CHIKV burden was negatively regulated by IL-17A signaling as both
Il17a-/- and Il17ra-/- mice exhibited lower CHIKV loads in their blood and milder
swelling in inoculated footpads compared to those of WT mice. These results suggest that
IL-17A signaling facilitates CHIKV replication and disease in mice.
During CHIKV infection, mice develop swelling in the infected footpad. Different
types of mouse models have been tested for swelling and other aspects of the disease.
Younger C57BL/6 neonatal mouse models show relevant disease manifestations as joint
swelling. This model also mimics the disease condition in children less than one year of
age as the virus is found in similar organs and with similar severity of disease (Couderc et
al, 2008). Infection in interferon receptor knockout mice results in greater disease
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severity as a result of which the immunodeficient mice rapidly succumb to death
(Couderc et al, 2008). Whatever may be the outcome, infection in all these mice shows a
similar trend in joint swelling. After subcutaneous inoculation of CHIKV via footpad,
biphasic swelling responses usually occur in the inoculated footpad. Two peaks of
swelling can be observed on around days 1-3 and 5-7 p. i., respectively. Mice also
develop severe arthritis, tendonitis, and fasciitis in the inoculated foot, but these
inflammatory effects are generally milder in the contralateral foot without swelling
(Acharya et al, 2015; Gardner et al, 2010; Morrison et al, 2011). Consistent with these
results, in our study, the major peak of CHIKV-induced footpad swelling occurred on day
6 p.i. Previous studies have shown that the infection of mice at the base of the tail
produces viremia but is unable to produce footpad swelling (Gardener et al, 2010). For
this reason, footpad infection was used as a better option for infection in this study.
Further, this mode of infection also fits better in comparison with the mode of natural
infection in humans through mosquito bites. However, the inoculation of the virus in one
hind foot did not result in a significant swelling of another hind foot. This represents a
weakness of this model because mosquito-mediated infection in humans results in the
swelling of multiple joints (Brighton et al, 1983; Ng et al, 2009). In immunocompetent
mouse models, the level of virus in the blood is greatly reduced from day 2 p.i. onwards
as is shown in this study, but the swelling of the footpads up to the days 6-7 p.i., when the
viruses had been cleared from the animal circulation, suggests that the second peak of the
swelling is largely mediated by pathogenic immune responses. Similar results were
observed in another study where inflammatory infiltrates appeared in the infected footpad
at day 7 p.i. (Morrison et al, 2011). CHIKV infected mice developed mixed inflammatory
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cell arthritis containing histiocytes, neutrophils, lymphocytes, and rare plasma cells in
joints and tarsi. They further developed severe chronic active tenosynovitis with
coagulative necrosis. Consistent with those results, our study also showed a greater influx
of immune cells in the infected footpads, and the damage and influx were even more in
the presence of IL-17A.
Type I IFN signaling has been shown to play an essential role in controlling
infections of alphaviruses including CHIKV (Couderc et al, 2008; Ryman et al, 2000;
Trgovcich et al, 1996). Inhibition of type I IFN signaling in mice causes severe CHIKVassociated disease due to higher viral loads and virus dissemination to the CNS (Couderc
et al, 2008; Laurent et al, 2008). As the major target cells, fibroblasts can be infected by
CHIKV in vitro and in vivo (Sourisseau et al, 2007; Schilte et al, 2010) and are the major
source of type I IFNs responding to CHIKV infection (Schilte et al, 2010). Our results on
NIH3T3 cells indicate that IL-17A inhibits IFN-α2 expression during CHIKV infection.
We also showed the same effect of IL-17A on the other cell types, such as bone marrow–
derived macrophages and dendritic cells, as well as mouse macrophage cells (Raw
264.7), suggesting that IL-17A inhibits IFN-α2 expression during CHIKV infection in a
cell-type independent manner. Blockade of IFN-α in mice results in the increase of
CHIKV viral loads in the infected foot and serum demonstrating its importance in
restricting viral replication and spread (Cook et al, 2019). Our in vitro results show that
CHIKV replication is supported by IL-17A, which may be due to the decrease of the
production of IFN-α2. We further showed that Ifn-α2 was upregulated in Il17a-/- and
Il17ra-/- mice compared to WT mice after CHIKV infection, which may be the reason for
lowering the level of CHIKV after infection. Our results further suggest that IL-17A, but
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not IL-17F, specifically inhibits the expression of IFN-α2 during CHIKV, but not WNV
or ZIKV infection. Both IL-17A and IL-17F belong to the same cytokine family and bind
to the same receptors, but their specificity and binding affinity to the receptors differ.
This might account for the differences observed in the inhibition of IFN-α2 and the
replication of CHIKV in the presence of IL-17A and IL-17F. Alphaviruses are known for
their antiviral counter defense strategies during infection; the C-terminal domain of
CHIKV nsP2 specifically inhibits IFN response by promoting the nuclear export of
STAT1 (Goertz et al, 2019). Further, alphaviruses have evolved mechanisms to obstruct
antiviral responses by inhibiting specific signaling pathways and modulating the host cell
shutoff by inhibiting general transcription and/or translation (Strauss and Strauss, 1994;
Gorchakov et al, 2004). These properties of CHIKV might be involved in the inhibition
of IFN-α2 expression during CHIKV infection, but not during WNV and ZIKV infection.
In mice, the family of type I IFN consists of 14 IFN-α subtypes and single forms
of IFN-β, IFN-ε, IFN-κ, and IFN-ω (Pesch et al, 2004). In response to viral infection,
host cell PRRs recognize the viral ligands and leads to the production of IFN-β and IFNα4 through activation of IRF-3 (Lin et al, 1998; Sato et al, 1998; Schafer et al, 1998;
Wathelet et al, 1998; Yoneyama et al, 1998). Through autocrine and paracrine signaling,
these IFNs modulate the expression of various transcriptional factors and ultimately
induce the expression of diverse IFN subtypes and IFN stimulated genes (ISGs). One of
the transcriptional regulators induced by these IFNs is IRF-7, which induces all other
IFN-α subtypes in a positive feedback loop, thus amplifying the response (Marie et al,
1998; Honda et al, 2006; Sato et al, 1998). Hence, IRF-3, IRF-5, and IRF-7 are
considered to be the master regulators of type I IFN induction and ISG expression. The
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combined effect of these three transcription factors has been shown to coordinately
regulate IFN response during WNV infection (Lazear et al, 2013). In lethal CHIKV
infection, the survival time of Irf3-/- Irf7-/- double knockout mice are longer than Ifnar1-/mice (Schilte et al, 2010), thus speculating that additional transcription factors, such as
IRF-5, contributes to the IFN response after CHIKV infection. Here, we show that IRF-3,
IRF-5, and IRF-7 are inhibited by IL-17A at the mRNA levels during CHIKV infection,
however, the phosphorylation of IRF-3 was not detectable by immunoblotting, suggesting
IRF-3 may not play an essential role mediating IL-17A-IFN-α2 pathway. Instead, the
expression and phosphorylation of Irf-5 and Irf-7 are inhibited by IL-17A, indicating that
IL-17A signaling inhibits IFN-α2 mainly by affecting IRF-5 and IRF-7 mediated
pathways. Type I IFNs bind to their receptors, initiating the JAK-STAT signaling
pathways, and induce the production of the ISGs that are critical to control viral
replication. Our results show the transcript levels of Isg-49 and Mx1 decrease in the
presence of rIL-17A and increase in the presence of IL-17A neutralizing antibody during
CHIKV infection, thus suggesting IL-17A directly or indirectly inhibits the ISG-49 and
Mx1-mediated antiviral responses against CHIKV replication.
Different IFN types may exert different functions during CHIKV infection. IFN-α
limits early viral replication and dissemination, while IFN-β modulates neutrophilmediated inflammation (Cook et al, 2019). Among IFN-α subtypes, IFN-α2 can be
induced by Herpes Simplex Virus, Respiratory Syncytial Virus, and Newcastle Disease
Virus (Loseke et al, 2003). It has antiviral effects against influenza A virus and human
metapneumovirus (Loseke et al, 2003; Moll et al, 2011; Scagnolari et al, 2011). We
found that IL-17A inhibits the expression of IFN-α2 during CHIKV infection in a variety
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of cell types. The level of IFN-α2 was decreased and the viral replication was increased
during CHIKV infection in the presence of rIL-17A. Our results also indicate only IFNα2, but not the other 10 tested IFN- α subtypes, is inhibited by IL-17A. Therefore, these
results suggest that the increase of the production of IFN-α2 in the absence of IL-17A
signaling may contribute to the reduced viral burden in the blood and footpad during
CHIKV infection. Supporting this hypothesis, we showed that the level of CHIKV is less
in the infected cells in the presence of recombinant IFNA2. This is consistent with the
previous research that has demonstrated that type I IFN signaling is essential to mitigate
CHIKV-induced pathogenicity in mice (Rudd et al, 2012; Cook et al, 2019). Furthermore,
we found that the infiltration of neutrophils into the footpads of Il17ra-/- mice was
significantly reduced compared to WT mice on day 6 p.i., when the second peak of
footpad swelling occurred. Neutrophils have been shown to be a major player
contributing to CHIKV-induced inflammation and tissue damage in joints (Poo et al,
2014). This may be due to the increased level of inflammatory mediators, such as
CXCL1, CXCL2, granulocyte colony-stimulating factor (G-CSF), IL-1β, and the
decreased level of anti-inflammatory macrophages. The lower viral burdens in the early
phase of CHIKV infection seen in Il17a-/- and Il17ra-/- mice may cause reduced levels of
these inflammatory mediators, thus leading to a less severe footpad swelling on day 6 p.i.
We further showed that Ifnar1-/- mice exhibit more severe footpad swelling and a
lower survival rate compared to WT mice. The viral load in blood is correlated to the
level of IL-17A in Ifnar1-/- mice. In severe infection, CHIKV can disseminate to the CNS
through the choroid plexus route (Grivard et al, 2007). Despite the fact that the viral load
in tissues other than blood and footpads was not measured in our study, it can be
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speculated that the death of the Ifnar1-/- mice was due to a higher viral burden and
increased viral dissemination to other tissues. Furthermore, we found that the infiltration
of neutrophils into the footpads of Il17ra-/- mice was significantly reduced compared to
WT mice on day 6 p.i. when the second peak of footpad swelling occurred. The lower
viral burdens in the early phase of CHIKV infection seen in Il17a-/- and Il17ra-/- mice,
may cause reduced levels of these inflammatory mediators, thus leading to a less severe
footpad swelling on day 6 p.i.
In conclusion, our study uncovers a novel role of IL-17A in inhibiting IFN-α2
production during CHIKV infection. Further studies are warranted to dissect the
mechanism by which IL-17A regulates CHIKV-induced IFN-α2 expression, which may
have broad implications in the understanding of IL-17A regulated immunity and the
development of novel IL-17A-based therapeutic strategy.
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- CONCLUSION AND FUTURE DIRECTIONS
6.1 Conclusion
During microbial infections, IL-17A can play different roles which may lead to
diverse immune functions. The innate immune system against viral infection is greatly
controlled by IFNs which prevent the growth and multiplication of the virus inside the
host. Studies have reported distinct roles of IFNs in controlling CHIKV replication and
assisting in the recovery process. In this study, we demonstrate that IL-17A facilitates
CHIKV replication in mice, resulting in more footpad swelling and tissue damage. This
enhancement of viral replication was mediated through the inhibition of IFN-2. In
addition, treatment of CHIKV-infected cells with recombinant IL-17A further inhibits the
level of IFN-2 and increases viral burden, whereas the treatment of the cells with IL17A neutralizing antibody antagonizes this effect, thus suggesting a potential therapeutic
role. Thus, this study discovers a novel role of IL-17A in inhibiting IFN-2 and
facilitating viral replication during CHIKV infection in cells and mice. Such relation
between IL-17A and IFNs may have implications in immunity against other viral
infections.
6.2 Future Directions
In this study, we found a novel function of IL-17A signaling in facilitating
CHIKV replication via inhibiting IFN-2 mediated antiviral ISG expression. A better
understanding of the mechanism in which IL-17A production leads to the inhibition of
IFN-2 in the context of CHIKV and other viral infections may have broad implications
in the understanding of IL-17A regulated immunity and the development of a novel IL17A-based therapeutic strategy. Therefore, detailed mechanisms are warranted for further
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investigations. In addition, the cellular source of IL-17A may be different during the
different stages of CHIKV infection and need to be further characterized in order to
develop an antiviral strategy by targeting IL-17A signaling pathways against CHIKV
infection.
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